Navigation Links
Trubion Announces Presentations at April/May Investor Conferences
Date:4/24/2008

SEATTLE, April 24 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN), today announced that executives will present an overview of the company at two upcoming investor conferences in April and May:
-- April 30: Morgan Stanley Global Healthcare Unplugged Conference at The

Ritz-Carlton, 455 Grand Bay Drive in Key Biscayne, FL. Dr. Peter

Thompson, president, CEO and chairman, is scheduled to present at

9:50 a.m. EDT. The presentation will be available via audio Webcast at

http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=TRBN&item_id=18.

-- May 13: Bank of America 2008 Health Care Conference at the Four

Seasons, 3960 Las Vegas Blvd S in Las Vegas, NV. Michelle Burris,

senior vice president and chief financial officer, is scheduled to

present at 1:20 p.m. PDT. The presentation will be available via audio

Webcast at

http://www.veracast.com/webcasts/bas/healthcare08/id62101185.cfm.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed candidates such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases developed under the company's Wyeth collaboration. Trubion's proprietary product candidate, TRU-016, is a novel CD37-targeted therapy for the treatment of B-cell malignancies currently in Phase 1/2 clinical evaluation. In addition to Trubion's current product candidates, the company is also developing additional alliance and proprietary product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: investors.trubion.com.

For more information, contact:

Trubion Pharmaceuticals, Inc.

Jim DeNike

Senior Director, Corporate Communications

206-838-0500

jdenike@trubion.com

Waggener Edstrom Worldwide Healthcare

Amy Petty

Senior Account Executive

617-576-5788

amyp@waggeneredstrom.com TRBN-G


'/>"/>
SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
2. Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
4. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
5. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
6. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results
7. Abbott Announces Labs Are Vital(TM) Facebook Scholarship Contest Winners
8. Environmental Tectonics Corporations BioMedical Division Announces Sale of Two Hyperbaric Chambers
9. Inverness Medical Innovations Announces First Quarter 2008 Results
10. Aida Pharmaceuticals, Inc. Announces Completion of Research Institute Acquisition
11. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Miami (PRWEB) , ... February 11, 2016 , ... ... opening of its new stem cell treatment clinic in Quito, Ecuador. The new ... orthopedic and trauma applications to patients from around the world. , The ...
(Date:2/10/2016)... Early-career researchers from Indonesia , ... and Yemen honored ... Indonesia , Nepal , Peru ... are being honored for their accomplishments in nutrition, psychiatry, biotechnology, women,s health, ... scientists who are pursuing careers in agriculture, biology and medicine in their ...
(Date:2/10/2016)... Ky. , Feb. 10, 2016 NX ... utilizing its proprietary NeXosome® technology for early warning ... of its most recent study by Dr. ... at the Society for Maternal Fetal Medicine,s (SMFM) annual ... GA, February 1-6 th , 2016.  The presentation reported ...
(Date:2/10/2016)... New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has joined the ... vaccines and immunotherapies for infectious diseases and cancer. , The Human ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint ... that Rising Market Are you interested in ... forecasts revenues for checkpoint inhibitors. Visiongain,s report gives ... submarket, product and national level. Avoid falling ... what progress, opportunities and revenues those emerging cancer ...
(Date:2/2/2016)... VIEW, Calif. , Feb. 2, 2016 /PRNewswire/ ... retinopathy market, Frost & Sullivan recognizes US-based Intelligent ... America Frost & Sullivan Award for New Product ... provider in North America , ... in the rapidly growing diabetic retinopathy market. The ...
(Date:2/1/2016)... ( www.wocketwallet.com ) announces the launch of a new video featuring singer, ... Las Vegas , where Joey appeared at the Wocket booth to ... , where Joey appeared at the Wocket booth to meet and greet ... the Consumer Electronics Show (CES2016) in Las Vegas , ... --> --> The video is ...
Breaking Biology News(10 mins):